Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Otsuka Holdings Co's Revenue for the
three
months ended in Mar. 2026 was €3,436 Mil. Otsuka Holdings Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was €3,002 Mil.
Hence, Otsuka Holdings Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.14.
Otsuka Holdings Co (STU:OS1) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Otsuka Holdings Co Receivables Turnover Related Terms
Otsuka Holdings Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Otsuka Holdings Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OS1 vs LLY, JNJ, ABBV: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Otsuka Holdings Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Otsuka Holdings Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Otsuka Holdings Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Otsuka Holdings Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Otsuka Holdings Co (STU:OS1) has a Receivables Turnover of 1.14 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Otsuka Holdings Co and its competitors. According to the industry distribution chart, Otsuka Holdings Co ranks #502 out of 950 companies in the Drug Manufacturers industry, placing it in the top 52.8%.
Is Otsuka Holdings Co's Receivables Turnover too high?
Otsuka Holdings Co's current Receivables Turnover is 1.14. The Drug Manufacturers industry median Receivables Turnover is 5.07. Otsuka Holdings Co's value of 1.14 is 77.5% below this industry median. Based on the distribution chart, Otsuka Holdings Co ranks #502 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Otsuka Holdings Co has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Otsuka Holdings Co's Receivables Turnover compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Otsuka Holdings Co ranks #502 out of 950 companies for Receivables Turnover. This places Otsuka Holdings Co in the lower half of its industry. The industry median Receivables Turnover is 5.07. Otsuka Holdings Co's value of 1.14 is 77.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Otsuka Holdings Co's current Receivables Turnover of 1.14 is 77.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Otsuka Holdings Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Otsuka Holdings Co's current Receivables Turnover is 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Otsuka Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Otsuka Holdings Co (STU:OS1) is currently considered Modestly Overvalued. The stock's GF Value™ is €45.13, compared to a current price of €57.50 — trading 27.4% above its estimated fair value. The current Receivables Turnover is 1.14 and 77.5% below the Drug Manufacturers industry median of 5.07. Otsuka Holdings Co's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Otsuka Holdings Co (STU:OS1), the current Receivables Turnover is 1.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Otsuka Holdings Co (STU:OS1) Overvalued in 2026?
Based on GuruFocus' analysis, Otsuka Holdings Co stock appears to be overvalued.
The current stock price of €57.50 is trading 27.4% above its estimated GF Value™ of €45.13.
GuruFocus considers Otsuka Holdings Co to be Modestly Overvalued.
Key valuation signals for STU:OS1:
Receivables Turnover: 1.14
GF Value™: €45.13 vs. price of €57.50 (27.4% above fair value)
Industry Position: 77.5% below the Drug Manufacturers median (#502 of 950)
No single metric tells the full story. See the STU:OS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Otsuka Holdings Co Ltd is a Japan-based company that operates in pharmaceuticals, nutraceuticals, and consumer products. It operates through four reportable segments: Medical-related Business, Nutraceutical-related Business, Consumer-related Business, and Other Business. The Medical Business manufactures and sells therapeutic drugs and infusions, the Nutraceutical Business produces functional foods, beverages, and nutritional supplements, the Consumer Business offers mineral water, beverages, and foods, while the Other Business provides storage services and manufactures chemicals and analytical equipment. It generates the majority of its revenue from the medical-related business segment.
88GF Score
Get the complete analysis for STU:OS1
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OS1 has been successfully added to your 
